Metin Kurtoglu - 02 Jan 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Chief Technology Officer
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Metin Kurtoglu
Issuer symbol
RNAC
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
06 Jan 2025, 16:19:37 UTC
Previous filing
11 Dec 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Award $0 +16,100 +32% $0.000000 67,133 02 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAC Employee Stock Option (right to buy) Award $0 +47,400 $0.000000 47,400 02 Jan 2025 Common Stock 47,400 $16.93 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.
F2 This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.